Provide a valuable resource to your clients or customers by linking to this resource page. Just place the following link on your website.
Degarelix is a prescription gonadotropin-releasing hormone receptor antagonist used for advanced prostate cancer. It is supplied as a powder for subcutaneous injection and is administered by a healthcare professional. Treatment begins with a larger starting dose, followed by a smaller maintenance dose every 28 days.
read more about degarelix ...Degarelix binds reversibly to gonadotropin-releasing hormone receptors in the pituitary gland. This reduces release of luteinizing hormone and follicle-stimulating hormone, followed by a decrease in testosterone production. Suppression of testosterone is the basis for its use in advanced prostate cancer.
Degarelix is indicated for patients with advanced prostate cancer. Current labeling does not establish safety and efficacy in children. Treatment is administered in the abdominal region by a healthcare professional, with injection sites varied to reduce local irritation.
The starting dose is 240 mg given as two separate 120 mg subcutaneous injections. Twenty-eight days later, treatment continues with 80 mg as one subcutaneous injection every 28 days. Degarelix is injected only in the abdominal region after the powder has been reconstituted with sterile water.
Serious concerns include severe hypersensitivity reactions and QT interval prolongation associated with androgen deprivation therapy. Injection-site pain, redness, swelling, and itching are common. Hot flashes, increased weight, reduced libido, and erectile difficulties can also occur. Electrocardiograms and electrolytes are considered in patients at increased risk for QT prolongation.
Degarelix is approved for treatment of advanced prostate cancer.
After the starting dose, 80 mg is administered once every 28 days.
Degarelix is injected subcutaneously into the abdominal region by a healthcare professional.
Yes. Androgen deprivation therapy with degarelix can prolong the QT interval in susceptible patients.
Degarelix Injection. MedlinePlus. https://www.medlineplus.gov/druginfo/meds/a609022.html. Date Accessed September 24, 2026.
Degarelix. National Cancer Institute. https://www.cancer.gov/about-cancer/treatment/drugs/degarelix. Date Accessed September 24, 2026.
Degarelix. PubChem. https://pubchem.ncbi.nlm.nih.gov/compound/16136245. Date Accessed September 24, 2026.
DailyMed - FIRMAGON (degarelix) kit. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ab11dd8a-0fd9-4013-89ab-e114557c7e4b. Date Accessed September 24, 2026.
FIRMAGON (degarelix for injection) Prescribing Information. Ferring Pharmaceuticals. https://www.ferringusa.com/wp-content/uploads/sites/11/2021/06/Firmagon-USPI-25feb2020.pdf. Date Accessed September 24, 2026.